Akido Raises $60 Million Series B to Expand Reach of ScopeAI, its Breakthrough Health Artificial Intelligence

Akido 获得 6000 万美元 B 轮融资，用于扩展其突破性健康人工智能 ScopeAI 的覆盖范围。

Akido’s ScopeAI is a first-of-its-kind system that fully integrates AI into a provider visit

Akido的ScopeAI是首个将人工智能完全融入诊疗过程的系统。

LOS ANGELES, May 15, 2025-- Akido Labs, Inc. (“Akido”), the AI and care delivery company reimagining healthcare, today announced it has raised $60 million in Series B funding. The round was led by Oak HC/FT with participation from Greco, SNR, and existing investors Y Combinator, Future Communities Capital, Jeff Dean (Chief Scientist, Google DeepMind & Google Research), and the Comprehensive Blood & Cancer Center.

洛杉矶，2025年5月15日——Akido Labs, Inc.（“Akido”），这家重新构想医疗保健的人工智能和护理服务公司，今天宣布已在B轮融资中筹集了6000万美元。本轮融资由Oak HC/FT领投，Greco、SNR以及现有投资者Y Combinator、Future Communities Capital、Jeff Dean（谷歌DeepMind和谷歌研究院首席科学家）和Comprehensive Blood & Cancer Center参与。

Funding will be used to expand the reach of ScopeAI, a system that increases clinical capacity and improves healthcare access..

资金将用于扩大ScopeAI的覆盖范围，这是一个提高临床能力和改善医疗保健获取的系统。

ScopeAI is transforming how Akido providers practice medicine – enabling them to care for dramatically more patients without compromising on quality. This unlocks time for providers to focus on complex cases, while increasing the total number of patients the system can support. The U.S. population requires over 3 billion doctor visits per year, yet only 825 million are currently available.

ScopeAI 正在改变 Akido 医疗提供者行医的方式——使他们能够在不降低质量的前提下，照顾更多的患者。这为医疗提供者节省了时间，可以专注于复杂病例，同时增加了系统能够支持的患者总数。美国人口每年需要超过 30 亿次医生问诊，但目前仅能提供 8.25 亿次。

The result is longer waits, especially for specialists, rushed appointments, and rising rates of preventable disease. Akido is addressing this crisis by embedding powerful medical intelligence directly into the clinical workflow – bringing scale, efficiency, and consistency to the front lines of care..

结果是等待时间更长，特别是专科医生，匆忙的预约，以及可预防疾病发病率的上升。Akido 正通过将强大的医疗智能直接嵌入临床工作流程来应对这一危机——为护理前线带来规模、效率和一致性。

“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage. With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers, and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography,” said Prashant Samant, Co-Founder & CEO of Akido.

“我们创建ScopeAI是为了应对全球医疗系统面临的最大挑战：医生短缺。由于对护理的需求远远超过供给，人工智能是解决全球医生赤字的关键，能够赋能医疗服务提供者，并确保患者无论经济状况或地理位置如何，都能获得及时、高质量的护理，”Akido联合创始人兼首席执行官Prashant Samant表示。

“At Akido, we believe exceptional healthcare is a basic human right. Our work has always focused on democratizing high quality healthcare, and this funding enables us to accelerate that mission.”.

“在Akido，我们相信卓越的医疗保健是基本人权。我们的工作一直专注于实现高质量医疗保健的民主化，这笔资金使我们能够加速推进这一使命。”

In a ScopeAI visit, a trained Medical Assistant (MA) meets with a patient, guided by intelligent prompts from ScopeAI throughout the encounter. ScopeAI uses clinical reasoning to actively listen, adapt in real time, and build a comprehensive understanding of the patient’s condition. Its scribing and auditory capabilities allow for dynamic conversation while simultaneously generating a full clinical report, including a preliminary diagnosis, treatment plan, and justification log for each decision it makes.

在一次ScopeAI问诊中，经过训练的医疗助理（MA）会在整个接诊过程中根据ScopeAI的智能提示与患者会面。ScopeAI运用临床推理来主动倾听、实时调整，并全面了解患者的病情。其记录和听觉功能使得动态对话成为可能，同时还能生成一份完整的临床报告，包括初步诊断、治疗计划以及每项决策的理由记录。

With ScopeAI, providers gain a deeper, more complete picture of a patient’s health with less time spent capturing it. An Akido provider can oversee a team of MAs conducting ScopeAI visits, increasing access to care while enabling the provider to focus on higher-acuity or more complex cases..

通过ScopeAI，医疗提供者能够以更少的时间获取患者健康的更深入、更完整的视图。Akido的提供者可以监督一支进行ScopeAI访问的医疗助理团队，在增加护理可及性的同时，使提供者能够专注于更高危或更复杂的病例。

Akido’s AI-based healthcare visits have delivered 5x more face-to-face time with patients and have achieved a 96 NPS score. With this new funding, Akido will accelerate the development and deployment of ScopeAI throughout its Akido Care medical network of 240 providers across 26 specialties. It will also help support Akido’s entrance into new markets like the recently announced first-of-its-kind healthcare program in New York City that is designed to address specific chronic diseases for professional rideshare and for-hire drivers..

Akido的基于人工智能的医疗访问使患者面对面交流的时间增加了5倍，并实现了96的净推荐值 (NPS)。通过这笔新资金，Akido将加速在其覆盖26个专业领域的240家供应商的Akido Care医疗网络中开发和部署ScopeAI。这笔资金还将支持Akido进入新市场，例如最近宣布的在纽约市推出的首个针对专业网约车和租赁司机特定慢性病的医疗计划。

“Akido is delivering on the promise of changing how patients experience a visit with their provider through AI,” said Andrew Adams, Co-Founder & Managing Partner at Oak HC/FT. “With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled.

“Akido正在兑现通过人工智能改变患者就诊体验的承诺，”Oak HC/FT的联合创始人兼管理合伙人Andrew Adams表示。“凭借其强大的纵向数据集，Akido在基础模型上有足够的精确性来提供临床准确性，而其他公司在这方面一直存在困难。”

We are excited to partner with their exceptional team of healthcare and technical operators to scale ScopeAI, expanding access to high-quality, AI-powered care for more patients.”.

我们很高兴与他们卓越的医疗和技术运营团队合作，扩大ScopeAI的规模，为更多患者提供高质量、人工智能驱动的护理。”

Akido was founded in 2015 with the goal of reimagining healthcare for historically vulnerable communities by leveraging AI and machine learning. In 2022, Akido launched Akido Care, a medical network that today includes nearly 100 clinics, offering primary and specialty care across 26 sub-specialties.

Akido成立于2015年，目标是通过利用人工智能和机器学习重新构想历史上脆弱社区的医疗保健。2022年，Akido推出了Akido Care医疗网络，如今已涵盖近100家诊所，提供覆盖26个亚专科的初级和专科医疗服务。

This dual strategy is what created the opportunity for Akido to leverage its proprietary dataset of over 10 million patient case studies and reinforcement-loop-human-feedback (RLHF) environment to launch ScopeAI. ScopeAI is one of the most sophisticated clinical AI systems available to providers, and it is continuously refined by incorporating real-time provider feedback.

这种双管齐下的策略为Akido利用其超过1000万患者案例的专有数据集和强化循环人类反馈（RLHF）环境创造了机会，从而推出了ScopeAI。ScopeAI是目前可供医疗人员使用的最精密的临床AI系统之一，并通过整合实时医疗人员反馈不断进行优化。

By integrating ScopeAI into the Akido Care medical network, Akido is positioned to empower providers to deliver highly personalized care to an individual patient while also scaling programs at a population level..

通过将ScopeAI整合到Akido Care医疗网络中，Akido能够帮助医疗服务提供者为个体患者提供高度个性化的护理，同时在群体层面扩展项目。

About Akido

关于合气道

Akido is pioneering a reimagined healthcare system with AI at its core; one that bridges artificial intelligence and empathy to bring exceptional healthcare to everyone. Its breakthrough technology unlocks the ability to transform the clinical experience, empowering providers and patients through an entirely new healthcare model.

Akido正在引领一个以人工智能为核心的医疗系统革新；这个系统将人工智能与同理心相结合，为每个人提供卓越的医疗服务。其突破性技术解锁了变革临床体验的能力，通过一个全新的医疗模式赋能医疗机构和患者。

Founded in 2015, Akido was created out of the University of Southern California’s Digital Health Lab with the idea that empowering government, healthcare, and nonprofit services with population-based data could help usher in a new era of preventive public health. Known for developing award-winning data and technology solutions, today Akido leverages its market-leading technology to power its bicoastal Akido Care medical network, which includes more than 240 providers and 90 clinics across both coasts and a patient base of nearly half a million.

Akido成立于2015年，源自南加州大学的数字健康实验室，其理念是通过基于人群的数据赋能政府、医疗保健和非营利服务，可以推动预防性公共卫生的新时代。该公司以开发屡获殊荣的数据和技术解决方案而闻名，如今Akido利用其领先的市场技术，支持其横跨东西海岸的Akido Care医疗网络，该网络包括超过240家医疗服务提供者和90家诊所，覆盖两岸，患者群体接近五十万。

For more information, please visit www.akidolabs.com..

欲了解更多信息，请访问 www.akidolabs.com。

About Oak HC/FT

关于Oak HC/FT

Oak HC/FT is a venture and growth equity firm specializing in investments in fintech and healthcare. Using partnership as a foundation, Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in over 85 portfolio companies and has over $5.3 billion in assets under management.

Oak HC/FT 是一家专注于金融科技和医疗保健领域投资的风险与成长股权公司。Oak HC/FT 以合作为基础，引导企业及创始人从种子阶段到成长阶段的每一步，打造产生可衡量且持久影响的业务。自 2014 年成立以来，Oak HC/FT 已投资超过 85 家投资组合公司，管理资产超过 53 亿美元。

Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at https://www.oakhcft.com/..

奥克HC/FT总部位于康涅狄格州斯坦福市，在加利福尼亚州旧金山设有办事处。在LinkedIn和X上关注奥克HC/FT，并访问https://www.oakhcft.com/了解更多。

Contact:

联系人：

Media

媒体

Jackie Kahn, jackie@oakhcft.com

杰基·卡恩，jackie@oakhcft.com